GlassScriptPhysician profile
John William Swisher
NPI 1083609564
$233,835.39
in general payments reported to CMS, 2019-2025
36 companies · $55K in 2025
The $55K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $9,942 · 2021: $10K · 2022: $26K · 2023: $44K · 2024: $72K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Food and Beverage: $10K · Travel and Lodging: $9,928 · Education: $96.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151,461.75 |
| Food and Beverage | $10,156.59 |
| Travel and Lodging | $9,928.20 |
| Education | $96.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $131,419.21 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $96,372.86 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Astrazeneca Pharmaceuticals LP | $1,354.85 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $925.32 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $437.11 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $325.94 | 2019-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $324.66 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $290.78 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $281.45 | 2020-2025 | Winrevair |
| Amgen INC. | $249.08 | 2022-2025 | Tezspire, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.52 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $199.89 | 2022-2024 | Glassia |
| Philips North America LLC | $181.81 | 2019-2024 | (Ak6) Vest Therapy |
| Abbott Laboratories | $145.99 | 2025 | 2nd Gen Centrimag Primary Console |
| Genzyme Corporation | $138.35 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $122.70 | 2023 | Briviact |
| Viatris Specialty LLC | $111.65 | 2025 | Yupelri |
| Baxter Healthcare | $106.69 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $85.63 | 2023-2024 | Yupelri |
| Gilead Sciences, INC. | $80.27 | 2019-2022 | |
| Sandoz INC. | $66.14 | 2024-2025 | Treprostinil |
| Shionogi INC | $55.33 | 2021-2023 | Fetroja |
| Pfizer INC. | $36.82 | 2022 | |
| Alexion Pharmaceuticals, INC. | $35.04 | 2021-2022 | |
| Liquidia Technologies, INC. | $34.09 | 2025 | Yutrepia |
| Electromed, INC. | $31.91 | 2024-2025 | Smartvest |
| Pulmonx Corporation | $25.45 | 2024 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Cmp Pharma, INC. | $25.13 | 2023 | Norliqva |
| Genentech USA, INC. | $20.04 | 2023 | Xolair |
| Janssen Pharmaceuticals, INC | $19.68 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $19.18 | 2024 | Purified Cortrophin Gel |
| La Jolla Pharmaceutical Company | $18.08 | 2025 | Giapreza |
| Novartis Pharmaceuticals Corporation | $18.00 | 2023 | |
| Phadia US INC. | $17.75 | 2024 | Immunocap |
| Inogen, INC. | $16.34 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.65 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Swisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.